Categories: Media Moves

Coverage: GlaxoSmithKline is buying Tesaro for $5 billion

The cancer-focused biotech Tesaro is being acquired by pharmaceutical giant GlaxoSmithKline PLC for $5.1 billion.

Adam Feuerstein of STAT had the news:

The deal values Tesaro at $75 per share, or a 63 percent premium to Friday’s closing price.

Tesaro’s drug Zejula belongs to a class of cancer drugs called PARP inhibitors that work by blocking an enzyme that cancer cells use to repair damage in their DNA. PARP inhibitors are also believed to be active in ovarian and prostate cancers, and are being studied in combination with immunotherapy drugs.

Zejula sales are expected to be in range of $233 to $238 million this year, according to Tesaro.

The pace of M&A in biotech has been generally lackluster this year, so GSK buying Tesaro right before 2018 closes will likely spark renewed optimism for new deals to come in 2019. It should be noted, however, that biotech company valuations have come down. Tesaro shares were trading for $75 at the beginning of the year, so this GSK buyout only gets the stock to break even.

Allison DeAngelis of the Boston Business Journal reported that Tesaro has sought-after technology:

Tesaro is an oncology-focused biotech developing ADP ribose polymerase (PARP) inhibitors, a much sought-after technology in recent years that’s particularly effective for patients with the BRCA gene mutation, a marker for increased risk of breast and ovarian cancer.

The price is a 63 percent premium to Tesaro’s market value as of Friday’s close. As of 9:50 a.m. on Monday, Tesaro’s shares had skyrocketed by 59 percent to $73.52, a sign that investors expect the deal will likely be completed.

The 8-year-old biotech received its first FDA approval last year for a secondary ovarian cancer treatment called Zejula, and is currently has a dozen clinical trials underway testing expanded uses for Zejula and other drugs. Zejula has brought in $166 million in revenue during the first nine months of 2018, and GlaxoSmithKline  valued Tesaro’s assets at $711 million.

Denise Roland and Kimberly Chin of The Wall Street Journal reported that GSK needs to expand its oncology pipeline:

But in buying Zejula, Glaxo is entering a competitive arena.

AstraZeneca PLC’s Lynparza is the market leader, and a third PARP inhibitor from Boulder, Colo.-based biotech company Clovis Oncology is also jostling for market share. All three are also racing to test their PARP inhibitors in other cancer types.

Zejula’s sales have lagged behind rivals, with doctors and industry officials saying the treatment’s side-effect profile is worse than the other drugs.

These concerns have given would-be buyers of Tesaro pause in the past. The company unsuccessfully explored the possibility of a sale more than a year ago. Since then, before Monday’s announcement, its share price has fallen.

Chris Roush

Chris Roush was the dean of the School of Communications at Quinnipiac University in Hamden, Connecticut. He was previously Walter E. Hussman Sr. Distinguished Professor in business journalism at UNC-Chapel Hill. He is a former business journalist for Bloomberg News, Businessweek, The Atlanta Journal-Constitution, The Tampa Tribune and the Sarasota Herald-Tribune. He is the author of the leading business reporting textbook "Show me the Money: Writing Business and Economics Stories for Mass Communication" and "Thinking Things Over," a biography of former Wall Street Journal editor Vermont Royster.

Recent Posts

Dynamo hires former Business Insider executive editor Harrington

Former Business Insider executive editor Rebecca Harrington has been hired by Dynamo to be its…

1 day ago

Bloomberg TV hires Kerubo as desk producer

Bloomberg Television has hired Brenda Kerubo as a desk producer in London. She will be covering Europe's…

2 days ago

Jittery CNBC staff reassured by new boss

In a meeting at CNBC headquarters Thursday afternoon, incoming boss Mark Lazarus presented a bullish…

2 days ago

Making business news accessible to a wider audience

Ritika Gupta, the BBC's North American business correspondent, was interviewed by Global Woman magazine about…

2 days ago

Rest of World hires Lo as China reporter

Rest of World has hired Kinling Lo as a China reporter. Lo was previously a…

2 days ago

Bloomberg rises to No. 7 biz news website

Bloomberg News saw strong unique visitor growth to its website in October, passing Fox Business…

2 days ago